Contrary to the "live forever" narrative, the primary goal of serious, government-funded aging research is to increase "healthspan"—the portion of life spent in good health. The focus is on addressing the societal challenge of aging populations by improving quality of life, not radically extending lifespan itself.

Longevity's goal shouldn't just be living free of disease ('health span'). The new frontier is 'performance span': actively maintaining the ability to perform at a high level, both physically and cognitively, well into old age, challenging the assumption that decline is inevitable.

Medical advances dramatically extended lifespans, but our culture and systems have not adapted. This "longevity paradox"—wanting to get old but not 'be' old—means we are unprepared for extended aging, having focused on the quantity of years over the quality of life within them.

While people are living longer, they are spending more of those years managing chronic illness and disability. This growing gap between lifespan (how long you live) and health span (how long you live well) points to a crisis in preventative and metabolic health.

Beyond tackling fatal diseases to increase lifespan, a new wave of biotech innovation focuses on "health span"—the period of life lived in high quality. This includes developing treatments for conditions often dismissed as aging, such as frailty, vision loss, and hearing decline, aiming to improve wellbeing in later decades.

A major transformation has occurred in longevity science, particularly in the last eight years. The conversation has moved away from claims of radical life extension towards the more valuable goal of increasing "healthspan"—the period of healthy, functional life. This represents a significant and recent shift in scientific consensus.

The current medical model, which treats diseases one by one as they appear, is flawed for an aging population. It extends life but leads to a rise in overall frailty and disability. The only effective path forward is to directly target the underlying biological process of aging to extend healthspan.

Data from the world's longest-lived populations shows the distribution of death is compressing, not shifting to older ages. More people are reaching old age, but the curve is getting tighter, proving a biological wall for average life expectancy around 87 years. This reinforces the need to focus on healthspan.

The common aversion to living to 120 stems from assuming extra years will be spent in poor health. The goal of longevity science is to extend *healthspan*—the period of healthy, mobile life—which reframes the debate from merely adding years to adding high-quality life.